#1 Clinical Trials Search in Europe

Trastuzumab

Trastuzumab, also known by the brand name Herceptin, is a targeted therapy drug used in the treatment of HER2-positive cancers, particularly breast cancer. This article explores various clinical trials investigating the use of trastuzumab in different cancer types, treatment combinations, and stages of disease. These studies aim to improve treatment outcomes, reduce side effects, and expand the drug’s applications in cancer care.

Table of Contents

What is Trastuzumab?

Trastuzumab, also known by its brand names Herceptin® and Trastuzumab Biosimilar, is a targeted therapy drug used in the treatment of certain types of cancer[1]. It belongs to a class of medications called monoclonal antibodies, which are laboratory-produced molecules designed to recognize and attach to specific proteins in the body[2].

How Trastuzumab Works

Trastuzumab works by targeting a protein called HER2 (Human Epidermal Growth Factor Receptor 2). Some cancer cells have an abundance of HER2 on their surface, which can promote rapid cell growth and division. Trastuzumab attaches to these HER2 receptors, blocking the signals that tell the cancer cells to grow. Additionally, it may help mark cancer cells for destruction by the body’s immune system[2][3].

Conditions Treated with Trastuzumab

Trastuzumab is primarily used to treat cancers that are HER2-positive, meaning they have high levels of HER2 protein. The main conditions treated with trastuzumab include:

  • Breast Cancer: Trastuzumab is approved for the treatment of HER2-positive breast cancer, both in early stages and metastatic (spread to other parts of the body) cases[2][4].
  • Gastric (Stomach) Cancer: It is also used in the treatment of HER2-positive advanced or metastatic gastric cancer[1].
  • Biliary Tract Cancer: Research is being conducted to evaluate the effectiveness of trastuzumab in treating HER2-positive biliary tract cancer, including cholangiocarcinoma (bile duct cancer)[5].

How Trastuzumab is Administered

Trastuzumab is typically administered in the following ways:

  • Intravenous (IV) Infusion: The drug is given through a vein in your arm. The first dose is usually given over 90 minutes, and subsequent doses may be given over 30 minutes if well-tolerated[1].
  • Subcutaneous (SC) Injection: In some cases, trastuzumab may be given as an injection under the skin[4].

The dosage and frequency of administration can vary depending on the specific condition being treated and the patient’s individual factors. Common regimens include:

  • Weekly doses: 4 mg/kg initial dose, followed by 2 mg/kg maintenance doses[1].
  • Every 3 weeks: 8 mg/kg initial dose, followed by 6 mg/kg maintenance doses[1].
  • Fixed dose of 600 mg every 3 weeks for subcutaneous injections[4].

Trastuzumab in Combination Therapies

Trastuzumab is often used in combination with other cancer treatments to enhance its effectiveness. Some common combinations include:

  • Trastuzumab with chemotherapy: This combination is frequently used in the treatment of HER2-positive breast and gastric cancers[1][4].
  • Trastuzumab with pertuzumab: Another targeted therapy that works synergistically with trastuzumab to block HER2 signaling[6].
  • Trastuzumab with paclitaxel: A chemotherapy drug often combined with trastuzumab for breast cancer treatment[4].

Potential Side Effects

While trastuzumab is generally well-tolerated, it can cause some side effects. The most significant potential side effect is cardiac toxicity, which is why heart function is closely monitored during treatment[4]. Other possible side effects may include:

  • Flu-like symptoms (fever, chills)
  • Nausea
  • Fatigue
  • Diarrhea
  • Headache

Your healthcare team will monitor you closely for any adverse reactions and adjust your treatment as necessary[4].

Ongoing Research and Future Directions

Researchers continue to explore new ways to use trastuzumab and improve its effectiveness. Some areas of ongoing research include:

  • Trastuzumab in early-stage breast cancer: Studies are investigating the use of trastuzumab as a single agent in neoadjuvant (before surgery) treatment for early-stage HER2-positive breast cancer[4].
  • Trastuzumab for brain metastases: Research is being conducted on the use of high-dose trastuzumab in combination with other drugs to treat HER2-positive breast cancer that has spread to the brain[6].
  • Trastuzumab in biliary tract cancer: Studies are evaluating the effectiveness of adding trastuzumab to standard chemotherapy for HER2-positive biliary tract cancers[5].
  • Trastuzumab biosimilars: Development and testing of biosimilar versions of trastuzumab to potentially increase accessibility and reduce costs[1].

These ongoing studies aim to expand the use of trastuzumab and improve outcomes for patients with HER2-positive cancers.

Aspect Details
Cancer Types Studied HER2-positive breast cancer, biliary tract cancer, urothelial carcinoma
Treatment Combinations Trastuzumab with chemotherapy (e.g., gemcitabine, cisplatin, paclitaxel), other targeted therapies (e.g., pertuzumab, pyrotinib, utomilumab)
Administration Methods Intravenous (IV), some studies exploring subcutaneous
Common Dosing Schedule Loading dose (often 8 mg/kg) followed by maintenance doses (often 6 mg/kg) every 3 weeks
Key Outcome Measures Pathological Complete Response (pCR), Progression-free Survival (PFS), Overall Survival (OS), safety and tolerability
Safety Concerns Cardiac toxicity, infusion-related reactions
Treatment Settings Neoadjuvant (before surgery), adjuvant (after surgery), metastatic disease
Emerging Research Areas Combination with newer targeted therapies, optimizing treatment duration, identifying predictive biomarkers

FAQ

  • What is trastuzumab and how does it work? Trastuzumab is a monoclonal antibody that targets the HER2 protein, which is overexpressed in some types of cancer, particularly breast cancer. It works by attaching to HER2 receptors on cancer cells, blocking their growth signals and helping the immune system identify and destroy these cells.
  • What types of cancer are being studied with trastuzumab in clinical trials? The clinical trials mentioned in this article focus primarily on HER2-positive breast cancer. However, there are also studies investigating its use in biliary tract cancer and urothelial carcinoma (a type of bladder cancer).
  • Are there any potential side effects of trastuzumab? Yes, some potential side effects of trastuzumab include cardiac toxicity, which is being closely monitored in several studies. Other possible side effects may include infusion-related reactions, fatigue, and nausea. The severity and frequency of side effects can vary depending on the individual and the specific treatment regimen.
  • How is trastuzumab typically administered in these clinical trials? In most of the trials mentioned, trastuzumab is administered intravenously (IV). The dosing schedule can vary, but it often involves a loading dose followed by regular maintenance doses every 3 weeks. Some studies are also exploring subcutaneous (under the skin) administration.
  • What are some of the combination therapies being studied with trastuzumab? Various combination therapies are being investigated, including trastuzumab with chemotherapy drugs like gemcitabine, cisplatin, and paclitaxel. Other studies are looking at combining trastuzumab with newer targeted therapies such as pertuzumab, pyrotinib, and utomilumab to potentially enhance its effectiveness.

Ongoing Clinical Trials on Trastuzumab

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +5

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Finland France Germany Italy Poland +1

  • A Study of Evorpacept Combined with Trastuzumab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France Italy Spain

  • Study of intraperitoneal paclitaxel combined with systemic therapy versus systemic therapy alone for patients with gastric cancer and peritoneal metastases

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands Norway Sweden

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Spain

  • Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

  • Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Hungary Italy +3

  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan and Drug Combination for Patients with HER2-Positive Gastric, GEJ, and Esophageal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Italy The Netherlands Poland Spain

  • Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +6

  • Study of trastuzumab with chemotherapy and immunotherapy combination for first-line treatment in patients with HER2-positive esophageal squamous cell cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark

Glossary

  • HER2: Human Epidermal growth factor Receptor 2, a protein that promotes the growth of cancer cells. When a breast cancer is HER2-positive, it means the cancer cells have a gene mutation that leads to excess HER2 protein production.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Trastuzumab is a monoclonal antibody designed to target HER2 proteins.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually before surgery. In breast cancer, this often involves chemotherapy and/or targeted therapies to shrink tumors before surgical removal.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk of cancer recurrence. In breast cancer, this may include additional targeted therapies, chemotherapy, or hormonal therapies.
  • Pathological Complete Response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with chemotherapy or radiation therapy.
  • Cardiotoxicity: Damage to the heart muscle or changes in heart rhythm caused by exposure to certain substances, including some cancer treatments like trastuzumab.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. In cancer, biomarkers can be used to help determine treatment options or monitor response to treatment.

References

  1. https://clinicaltrials.gov/study/NCT04181333
  2. https://clinicaltrials.gov/study/NCT04986579
  3. https://clinicaltrials.gov/study/NCT02167854
  4. https://clinicaltrials.gov/study/NCT05388500
  5. https://clinicaltrials.gov/study/NCT03613168
  6. https://clinicaltrials.gov/study/NCT03417544